ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018
Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cost patterns of long-term prescribed medications in patients with multiple sclerosis in Germany.Scientific reports · 2025Article
- Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.Journal of neurology · 2025Article
- Article
- The economic impact of comorbidity in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Polypharmacy and multiple sclerosis: A population-based study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Article
- Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic Risks.Frontiers in neurology · 2022Article
- Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.PloS one · 2022Article
- Article
- Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden.PharmacoEconomics - open · 2020Article
- Article
- The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research.European journal of epidemiology · 2019Review
- How Cost-of-Illness (COI) Study Provides Direct and Indirect Costs of Multiple Sclerosis (MS) in Bosnia and Herzegovina ?Materia socio-medica · 2018Article
- Article
- Changes in disability in people with multiple sclerosis: a 10-year prospective study.Journal of neurology · 2018Article
- Impact on healthcare resource utilization of multiple sclerosis in Spain.BMC health services research · 2017Article
- Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Cognitive function predicts work disability among multiple sclerosis patients.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMultiple sclerosis (MS) causes work disability and healthcare resource use, but little is known about the distribution of the associated costs to society.
objectivesWe estimated the cost of illness (COI) of working-aged individuals with MS, from the societal perspective, overall and in different groups.
methodsA population-based study was conducted, using data linked from several nationwide registers, on 14,077 individuals with MS, aged 20-64 years and living in Sweden. Prevalence-based direct and indirect costs in 2010 were calculated, including costs for prescription drug use, specialized healthcare, sick leave, and disability pension.
resultsThe estimated COI of all the MS patients were SEK 3950 million, of which 75% were indirect costs. MS was the main diagnosis for resource use, causing 38% of healthcare costs and 67% of indirect costs. The distribution of costs was skewed, in which less than 25% of the patients accounted for half the total COI.
conclusionsIndirect costs contributed to approximately 75% of the estimated overall COI of MS patients of working age in Sweden. MS was the main diagnosis for more than half of the estimated COI in this patient group. Further studies are needed to gain knowledge on development of costs over time during the MS disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.